Intervention Review

Ketanserin for Raynaud's phenomenon in progressive systemic sclerosis

  1. Janet Pope1,*,
  2. D Fenlon2,
  3. A Thompson3,
  4. Beverley Shea4,
  5. Dan Furst5,
  6. George A Wells6,
  7. Alan Silman7

Editorial Group: Cochrane Musculoskeletal Group

Published Online: 27 APR 1998

Assessed as up-to-date: 9 SEP 2007

DOI: 10.1002/14651858.CD000954

How to Cite

Pope J, Fenlon D, Thompson A, Shea B, Furst D, Wells GA, Silman A. Ketanserin for Raynaud's phenomenon in progressive systemic sclerosis. Cochrane Database of Systematic Reviews 1998, Issue 2. Art. No.: CD000954. DOI: 10.1002/14651858.CD000954.

Author Information

  1. 1

    University of Western Ontario, Dept of Medicine and Epidemiology and Biostatistics, London, Ontario, Canada

  2. 2

    London Health Sciences Centre, University of Western Ontario, Department of Surgery, London, Ontario, Canada

  3. 3

    St Joseph's Health Care, Department of Rheumatology, London, Ontario, Canada

  4. 4

    University of Ottawa, Institute of Population Health, Ottawa, Ontario, Canada

  5. 5

    Virginia Mason Research Center, Seattle, WA 98101, USA

  6. 6

    University of Ottawa Heart Institute, Cardiovascular Research Reference Centre, Ottawa, Ontario, Canada

  7. 7

    University of Manchester, ARC Epidemiology Research Unit, Manchester, UK

*Janet Pope, Dept of Medicine and Epidemiology and Biostatistics, University of Western Ontario, St. Joseph's Health Care, 268 Grosvenor St, London, Ontario, N6A 4V2, Canada. Janet.Pope@sjhc.london.on.ca.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 27 APR 1998

SEARCH

 

Abstract

  1. Top of page
  2. Abstract
  3. Plain language summary
  4. 摘要

Background

Scleroderma is a connective tissue disease causing fibrosis and commonly affects the skin and internal organs such as the GI tract, lungs, kidney and heart. Most people with scleroderma also have Raynaud's phenomenon (RP). One of the possible treatment options for RP in scleroderma is ketanserin.

Objectives

To assess the effects and toxicity of ketanserin versus placebo for the treatment of Raynaud's phenomenon (RP) in scleroderma.

Search methods

We searched the Cochrane Controlled Trials Register, and Medline up to August 1, 2007 using the Cochrane Collaboration search strategy developed by Dickersin et al.(1994). Key words included: Raynaud's or vasospasm, scleroderma or progressive systemic sclerosis or connective tissue disease or autoimmune disease. Current Contents were searched up to and including August 1, 2007. All bibliographies of articles retrieved were searched and key experts in the area were contacted for additional and unpublished data. The initial search strategy included all languages.

Selection criteria

All randomized controlled trials comparing ketanserin versus placebo were eligible if they reported clinical outcomes of interest. Trials with dropout rates greater than 30% were excluded.

Data collection and analysis

All data were abstracted by two independent and trained reviewers (SH, PT), and verified by a third reviewer (JP). Each trial was assessed independently by the same two reviewers for its quality using a validated quality assessment tool (Altman 2001).

Peto's odds ratios were calculated for all dichotomous outcomes and a weighted mean difference was carried out on all continuous outcomes. Fixed effects and random effects model were used if the data was homogeneous or heterogeneous, respectively.

Main results

Six trials and 146 patients were included. The proportion improved was significantly better in the group on ketanserin with a Peto's odds ratio (OR) of 2.74 (95% CI 1.42, 5.11) (Cadranel 1986; Dormandy 1988; Kirch 1987; Lukac 1985; van de Wal 1987). When comparing ketanserin to placebo, the decrease in frequency of RP attacks favoured placebo and was statistically significant [WMD (fixed) 25.20 (95% CI 22.55,27.85)] (Kirch 1987). Side effects were significantly more common in the group using active treatment [Peto's OR 2.63 (95% CI 1.42, 4.88)] (Cadranel 1986; Kirch 1987; Lukac 1985; Ortonne 1989; van de Wal 1987). Duration of attacks significantly favoured the placebo group over the active treatment [WMD (fixed) 4.10 (95% CI 3.57, 4.63)] (Kirch 1987).

Authors' conclusions

Ketanserin may have some efficacy in the treatment of Raynaud's phenomenon secondary to scleroderma. Overall, ketanserin is not significantly different from placebo for the treatment of Raynaud's phenomenon except for some decrease in the duration of attacks and more subjects improved on ketanserin compared to placebo. However, there were more side effects, and the frequency of attacks actually favored placebo. It can be concluded that ketanserin treatment in Raynaud's phenomenon secondary to scleroderma is not clinically beneficial.

 

Plain language summary

  1. Top of page
  2. Abstract
  3. Plain language summary
  4. 摘要

Ketanserin is a drug that has been studied in the treatment of Raynaud's phenomenon and associated conditions. It is not widely used however.

Raynaud's phenomenon is a disease that causes decreased blood flow and circulation to the extremeties. Symptoms include discolouration, pain, and in some severe cases ulceration of the hands and feet. It is most often triggered by cold, stress, and emotional discomfort. Primary Raynaud's phenomenon has no underlying disease associated with it. Secondary Raynaud's phenomenon is most often associated with scleroderma, but may also be related to systemic lupus erythematosus, mixed connective tissue disease, Sjorgen's syndrome, dermatomyositis, or rheumatoid arthritis. Scleroderma is a connective tissue disease causing hardening and commonly affects the skin and internal organs such as the GI tract, lungs, kidney and heart.

Six trials which investigated the effect of ketanserin on 146 patients with either primary Raynaud's phenomenon or Raynaud's phenomenon secondary to systemic sclerosis were included (Cadranel 1986; Dormandy 1988; Kirch 1987; Lukac 1985; Ortonne 1989; van de Wal 1987). Patients treated with ketanserin experienced a greater improvement in mean functional index scores and more patients improved than those treated with placebo, however they also experienced more side effects and an increase in the frequency and duration of attacks.

This review assessed a limited number of studies and therefore the conclusions reached need to be investigated further.

 

摘要

  1. Top of page
  2. Abstract
  3. Plain language summary
  4. 摘要

背景

Ketanserin用於治療全身性硬化症之雷諾氏症現象

Ketanserin曾被研究用於治療改善硬皮症之表徵包括雷諾氏症現象

目標

評估Ketanserin與安慰劑用於治療硬皮症之雷諾氏症的效果與毒性比較

搜尋策略

搜尋包括the Cochrane Controlled Trials Register, MEDLINE (直到1996年)。關鍵字包括Raynaud's or vasospasm, scleroderma or progressive systematic sclerosis or connective tissue disease or autoimmune disease,Current Contents搜尋到1997年4月7日。同時手動搜尋文章之參考文獻,及詢問專家其它發表及未發表文獻。初步搜尋包括所有語言。

選擇標準

所有比較Ketanserin與安慰劑且報告有興趣臨床結果之隨機對照試驗研究。排除病患流失率超過35% 的研究。

資料收集與分析

兩位作者獨立進行資料摘錄。本文使用Peto's odds ratios來計算二分法的資料,使用加權平均差異(weighted mean difference:WMD)來分析連續性資料。並用固定效應模型(fixedeffects model)或隨機效應模型(randomeffects model)分別來檢定分析同質或異質性的資料。

主要結論

3篇研究,共有66例病患包含於分析中。在ketanserin治療組進步比率較多OR 4.80 (95% CI 1.33, 17.37)。但在發作發作嚴重度減少方面,安慰劑組減少比ketanserin組多,但未達顯著上差異。副作用在治療組較多OR 5.96 (95% CI 1.61, 22.06),ketanserin組發作頻率未改變,但發作時間顯著減少。

作者結論

Ketanserin在治療硬皮症之雷諾氏症可能有些效果。整體而言,Ketanserin比安慰劑組僅在發作時間有些減少及改善患者較多外,與安慰劑組無統計上顯著差異,但有較多副作用。可下結論認為Ketanserin在治療硬皮症之雷諾氏症臨床並無臨床優點。

翻譯人

本摘要由林口長庚醫院余光輝翻譯。

此翻譯計畫由臺灣國家衛生研究院(National Health Research Institutes, Taiwan)統籌。

總結

無總結